PAC1R/CRE-Luc/HEK293
CBP71454
詢(xún) 價(jià)
索取Protocol
產(chǎn)品描述
產(chǎn)品數據庫
| I. Background | |
| The PAC1 receptor/PACAP-38 pathway has been proposed as a novel target for the teament of migraine. In response, Amgen developed an anti-PAC1 receptor monoclonal antibody that has completed phase 2 clinical evaluation in patients with chronic or episodic migraine. | |
| II. Introduction | |
| Host Cell: |
HEK293 |
| Stability: | 20 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | DMEM+10%FBS+2ug/ml puromycin+200ug/ml hygromycin |
| Mycoplasma Status: | Negative |
| Storage: | Liquid nitrogen immediately upon delivery |
| Application(s): |
Functional assay for PAC1R |
| Transducer: | Gs+Gq |
| Ⅲ. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | kidney |
| Morphology: | Epithelial |
| Growth Properties: | Adherent |
| Ⅳ. Representative Data | |
|
Figure 1. Recombinant PAC1R/CRE-Luc/HEK293 cell stably expressing PAC1R.
Figure 2.Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001（we strongly suggest to purchase from Cobioer). Dose Response of PACAP 1-38 in PAC1R/CRE-Luc HEK293 Cells(C9). |
|
